Introduction
Mitochondria have important functions in mammalian cells, such as serving the energy powerhouse and integrators of the intrinsic pathway of apoptosis (Kroemer et al., 1998 (Kroemer et al., , 2007 Desagher and Martinou, 2000) . Apoptosis implies the translocation or the association of cellular proteins to the membrane of mitochondria, such as proteins triggering the mitochondrial membrane permeabilization (MMP) and the release of several pro-apoptotic factors including cytochrome c, AIF, smac/DIABLO and caspases from the intermembrane space to the cytosol. Collectively, these events contribute to the initiation of the final stages of cell death. MMP is currently considered as the point-ofno-return in the lethal cascade and a promising therapeutic target, as its pharmacological or genetic inhibition prevents cell death under many circumstances (Costantini et al., 2000b; Bouchier-Hayes et al., 2005; Fulda et al., 2010) .
A number of pathological states, most prominent being cancer, has been associated with or results from a mitochondrial dysfunction and impairment in MMP induction. Mitochondria can contribute to oncogenesis through a variety of mechanisms, including mutations of nuclear or mtDNA-encoded mitochondrial tumor suppressors, metabolite accumulation (for example succinate and fumarate), production of reactive oxygen species (ROS), apoptosis resistance, hypoxia-like pathway activation and bioenergetic dysfunction (Gottlieb and Tomlinson, 2005) . Thus, in certain tumor cells, the decreased adenosine triphosphate (ATP) production through mitochondrial oxidative phosphorylation is balanced by an increased ATP synthesis by glycolysis to maintain a vital energetic homeostasis, as first described by Warburg et al. (1924) and Warburg (1956) . However, non-Warburg tumor cells in which oxydative phosphorylation is used primarily to generate ATP rather than glycolysis have also been previously described, notably in gliomas cells (Bouzier et al., 1998; Beckner et al., 2005; Griguer et al., 2007; Rodrı´guez-Enrı´quez et al., 2010) . Among the proteins responsible for mitochondrial dysfunction in cancer, the mitochondrial adenine nucleotide translocase (ANT) or ADP/ATP carrier has been suggested to have an important function (Faure Vigny et al., 1996; Halestrap and Brenner, 2003; Chevrollier et al., 2005a; Brenner and Grimm, 2006) .
ANT is an integral protein inserted into the mitochondrial inner membrane (IM) through six transmembrane helices as revealed by 3D-structure analysis (Pebay-Peyroula et al., 2003) . Its structure is similar to that predicted for other mitochondrial carriers and then allows the electrogenic exchange of two substrates, namely ADP and ATP, between the matrix and the intermembrane space (Pfaff and Klingenberg, 1968; Pfaff et al., 1969) . Therefore, this nucleotide-dependent function implies a central role in energetic metabolism and energetic compartmentation via the coupling of mitochondrial ATP synthesis to cytosolic delivery. Then, ANT antiport function is critical for many cell processes, notably in tumor cells, which have increased metabolic requirements for DNA and protein synthesis (Gottlieb and Tomlinson, 2005) .
In 1996, the discovery that ANT also functions as a non-specific pore upon stimulation by ions and a variety of molecules, such as calcium (Ca 2 þ ) and ROS, as shown by reconstitution of native purified ANT into liposomes, constituted the first important breakthrough (Brustovetsky and Klingenberg, 1996; Ru¨ck et al., 1998) . Later, a second breakthrough highlighted the critical involvement of ANT in the execution of the mitochondrial apoptosis pathway in various pathophysiological and experimental models, such as ischemiareperfusion, intoxication and chemotherapy (Marzo et al., 1998a; Cao et al., 2001; Haouzi et al., 2002; Malorni et al., 2009) . For instance, ANT could influence cell death through cooperation with pro-apoptotic proteins such as Bax, viral proteins (for example viral protein R (Vpr) from HIV-1, PB1-F2 from Influenza) or through participation in a mitochondrial polyprotein complex, the so-called permeability transition pore complex (PTPC) in diverse model systems such as human carcinoma cell lines, cardiomyocytes and neurons (Crompton, 1999; Cao et al., 2001; De Giorgi et al., 2002; Brenner and Grimm, 2006) (Figure 1 ). However, while experimental evidence clearly established a role of ANT in the so-called MMP in some models of cancer, other studies also showed that MMP could be ANT independent, but controlled by the Bcl-2 family of proteins (Antonsson et al., 1997; Eskes et al., 1998) . Bcl-2 family is composed of pro-and anti-apoptotic proteins that coordinate mitochondrial outer membrane permeabilization via still debated molecular mechanisms (for review, see Chipuk and Green, 2008) . More recently, a third major breakthrough has been made in terms of role of ANT in apoptosis. Thus, ANT is expressed as four tissue-specific isoforms, ANT1 to ANT4, and we and others postulated that each ANT isoform might have a specific role in influencing cell fate, notably in cancer cells (Bauer et al., 1999; Zamora et al., 2004a; Le Bras et al., 2006; Gallerne et al., 2010) . In this review, we recapitulate our knowledge of the role that the various isoforms of ANT play in apoptosis, examine the expression and the function of the four ANT isoforms in cancer cells and discuss recent evidence to propose a novel classification of ANT isoforms and their function in cancer cell death.
ANT: a bi-functional protein ANT, as many proteins involved in cell death signaling, harbors two (opposite) functions, both of which are intricately involved in the control and regulation of cell fate (Halestrap and Brenner, 2003; Kroemer, et al., 2007) .
A vital ADP/ATP translocase function ANT constitutes the major protein in the mitochondrial IM, in which it represents around 10% of the proteins. It catalyzes the energetic process of ATP export from the mitochondrial matrix to the intermembrane space, and conversely, the import of ADP from the intermembrane space to the matrix (Pfaff and Klingenberg, 1968; Pfaff et al., 1969 Figure 1 Scheme of mitochondrial functions involving the ANT. ANT possess diverse functions including the electrogenic exchange ADP/ATP across the IM, the participation to the PTPC stimulate by Ca 2 þ and ROS, a mild uncoupling activity that is stimulated by anion superoxide, fatty acids and peroxydated lipids. All functions are modulated by the transmembrane inner potential, DCm, which is, at least in part, generated by the oxidative phosphorylation and the function of the respiratory complexes I to V. Cytc, cytochrome c; G6P, glucose-6-phosphate HK, hexokinase, TCA, tricarboxylic acid cycle; U, calcium uniport; UCP, uncoupling protein.
ANT isoforms family C Brenner et al extensively characterized in isolated mitochondria from various tissues with radiolabeled nucleotides and in native ANT-containing proteoliposomes (Vignais et al., 1973; Lauquin et al., 1979; Brandolin et al., 1980) . These studies have benefited from the use of various inhibitors (for a list of ANT inhibitors, see Table 1 ), and mainly, two specific inhibitors, namely carboxyatractyloside (CAT) and bongkrekic acid (BA), which bind different sites within the ANT 3D structure and favors, respectively, c-and m-conformation of the protein (Henderson and Lardy, 1970; Vignais et al., 1973; Klingenberg, 2008) . The efficiency of the carrier to exchange ADP and ATP is moderate and the carrier abundance would reflect an adaptation to the high intracellular demand of ATP export (Klingenberg, 2008) . It is still a matter of debate whether ANT can function independently or requires a physical association with a partner such as voltage-dependent anion channel (VDAC) (Beutner et al., 1998) , the phosphate carrier (PiC) (Leung et al., 2008) , the F 0 F 1 -ATP synthase (Chen et al., 2004) as well as the intermembrane space creatine kinase in certain tissues (Beutner et al., 1998) (Figure 1 ). An association with a mitochondrial partner may improve the channeling of ATP to hexokinase and ADP to the matrix, to answer to the cellular energetic demand, and may be particularly relevant in the context of metabolic adaptation of mitochondria in cancer cells. Recently, the crystallization of the bovine heart ANT with the specific inhibitor, CAT, has confirmed a particular structural organization based on six transmembrane helices with a depression at the intermembrane space surface and a short mitochondrial carrier sequence (RRRMMM) facing the mitochondrial matrix (Pebay-Peyroula et al., 2003) (Figure 2) . Interestingly, the ANT crystal analysis confirmed the existence of a threefold repeat of about 100 amino acids and the binding of the IM-specific lipid cardiolipin, whereas it is inferred that the monomer is the preferential state to transport the nucleotides. CAT binding was observed to be exclusive to nucleotides, thus suggesting that amino acids involved in the putative nucleotide-binding site are also important for CAT binding. A closed-open conformation switch has been proposed to allow for the transport of nucleotides; however, the exact molecular enzymatic mechanism of ADP/ATP exchange still remains unclear (Pebay-Peyroula et al., 2003) .
As indicated above, adaptation of (most) cancer cells to intra-tumoral hypoxia is manifested by decreased oxidative phosphorylation and a high glycolytic ATP production (Warburg, 1956; Gottlieb and Tomlinson, 2005; Bellance et al., 2009) . To maintain cellular ATP homeostasis, mitochondria regulate the expression of several nuclear and mitochondrial genes, including ANT isoforms (Chevrollier et al., 2005a; Bellance et al., 2009) . Thus, it has been postulated that cancer cells overexpress ANT2 isoform (Chevrollier et al., 2005a) , which would function in a reverse manner, that is import of ATP and export of ADP, to compensate for the low efficiency of ATP production via oxidative phosphorylation and to promote cell growth (see below for review of the putative promoter regions involved in ANT2 upregulation). In addition, cytosolic hexokinase II associates with porin or VDAC to transfer cytosolic ATP to ANT2. The latter is in close functional interaction with 
Abbreviations: ANT, adenine nucleotide translocase; ATP, adenosine triphosphate; ND, not determined; ( þ ), activation; (À), inhibition. This table lists small molecules, ions, proteins acting directly on ANT. Effects of ANT activity modulation have been determined into artificial membranes (e.g. liposomes or planar lipid bilayers) in which native ANT has been reconstituted. ANT has been purified from various organs and animals in the presence of Triton X-100 and reconstituted into artificial biomembranes. The pore function has been measured by electrophysiology or by measurement of the release of fluorescent probe or of a metabolite from proteoliposomes. The effect on cell death has been evaluated on cancer cell lines or primary neurons.
ANT isoforms family C Brenner et al F 0 F 1 -ATP synthase to form the supercomplex ATP synthasome (Chen et al., 2004) .
A lethal pore function
The initial description of ANT was exclusively restricted to its functional involvement in the exchange of nucleotides. However, the Ca 2 þ -induced opening of a large conductance channel through the IM was reported in a setup of isolated rat liver mitochondria Szabo, 1994, 1995) . This channel activity was attributed to PTPC opening and modulated by ANT inhibitors, CAT and BA, as well as by endogenous ligands, ADP and ATP. These studies constitute the basis for the controversial hypothesis that ANT could be the IM channel of the PTPC in association (or not) with VDAC and cyclophilin D (CypD) Szabo, 1994, 1995) . These and other observations provide evidence that ANT is located in the contact sites of mitochondrial membranes in complex with VDAC and other proteins, such as creatine kinase and CypD (Vyssokikh and Brdiczka, 2003) . However, despite the use of multiple methodologies, such as co-immunoprecipation, proteomic analysis, co-purification, genetic validation, the identity and the number of PTPC components are still elusive (Zoratti et al., 2005; Brenner and Grimm, 2006; Halestrap, 2009; Rasola et al., 2010) and it remains to be seen whether ANT and VDAC are the main components of the PTPC or just regulators or accessory PTPC proteins. Notably, using isolated mitochondria from mice knock-out for ANT 1/2 or, VDAC1, or VDAC3, or VDAC1/3 and CypD, a permeability transition response to the classical inducer Ca 2 þ was monitored and results suggested a limited role for these proteins in MMP (for discussion, see Rasola et al., 2010) . Interestingly, the PiC has been proposed recently to function as the IM channel of PTPC (Leung et al., 2008) , but this awaits genetic demonstration. Finally, an attractive possibility might be that the composition of this pore varies depending on the tissue as well as the pathophysiological state (Halestrap, 2009 , Rasola et al., 2010 .
Irrespective of these premises, Brustovetsky and Klingenberg (1996) used electrophysiological approaches to show that pure native ANT could be converted into a large channel by Ca 2 þ following reconstitution into liposomes (Brustovetsky and Klingenberg, 1996) . The channel activity consisted of multiple substates that are sensitive to ANT inhibitors, ANT ligands and insensitive to cyclosporin A (CsA), a molecule that maintains PTPC in a closed conformation by inhibition of the interaction of ANT and CypD. Importantly, this conversion was reversible by Ca 2 þ elimination, indicating that the pore channel conformation is not a denatured substate of the protein in which the global 3D structure has been irreversibly lost (Brustovetsky and Klingenberg, 1996) . The ADP/ATP carrier-pore conformation change may result from the binding of Ca 2 þ to cardiolipin, an IM lipid, which disrupts the association of the lipid with ANT (Klingenberg, 2008) . The possibility to induce a conversion into a pore upon ligation has been repeated and extended to several mitochondrial carriers (Rial et al., 2010) , revealing a novel inducible function for some members of this highly conserved class of mitochondrial proteins. However, not all carriers support the induction of mitochondrial permeability transition pore (Crichton et al., 2009) .
Moreover, despite being less active than the uncoupling protein 3, a mitochondrial carrier, ANT might import proton across the IM and thus, might have a role in mediating mild uncoupling to regulate ROS generated by the electron transport chain. This supports the hypothesis that ANT participates to a first line of defense against ROS in response to fatty acids, superoxide and lipid peroxidation products under conditions of high oxidative damage (Figure 1) (Scho¨nfeld et al., 1996; Khailova et al., 2006; Azzu et al., 2008; Jastroch et al., 2010; Toime and Brand, 2010) . This ANT , 2003) . N-and C-terminal extremities (Nt, Ct), which face the intermembrane space are indicated. The ADP/ATP translocase inhibitor CAT is shown in yellow and cardiolipins residues in brown. Two sites proposed to be important for the modulation of the pore function are indicated: the second hydrophilic loop (position 104-116, red), a putative-binding site for Bax, Bcl-2 and Vpr 52-96 and an oxidable cystein (position 56, orange).
ANT isoforms family C Brenner et al uncoupling function has undoubtedly important implications for pathology and cardioprotection (Nadtochiy et al., 2006) , but remains to be investigated in cancer. Interestingly, the functions of ANT could depend on the dynamics of the mitochondrial networks, that is the balance between the mitochondrial fusion/fission events. Thus, it has been shown that the inhibition of mitochondrial fission in the heart by pharmacological as well as genetic approaches impairs the process of permeability transition and cell death (Gazaryan and Brown, 2007; Ong et al., 2010) . Thus, this suggests that inhibition of fission could prevent the lethal ANT pore opening within the PTPC, but again, this requires further investigation in appropriate experimental cancer models.
Paradoxically, ANT function modulation could influence the bioenergetic metabolism and cell fate through pore activation as well as carrier inactivation. Thus, even if it might be difficult to discriminate which function is involved in a particular condition, there is now a reasonable consensus that ANT can be specifically converted into a pore upon treatment with a large panel of proteins and molecules and that, upon a certain threshold of stimulus, ANT pore induction can lead to cell death (Table 1) . For example, we and others showed that ANT cooperates with Bax to modulate the ANT translocase and pore activity (Belzacq et al., 2003) and to induce pro-apoptotic MMP in various cancer cells (Marzo et al., 1998a) . Importantly, inhibition of this protein-protein interaction by CsA, z-VAD-fmk (a caspase inhibitor) and furosemide (a Bax translocation inhibitor) prevented cell death induction by chemotherapy (Verrier et al., 2004) . This observation suggests that in colon carcinoma cells treatment by etoposide, which inhibits the topoisomerase II and, therefore, generates a genotoxic damage, caspase activation precedes the induction of MMP and cell death by an unknown mechanism. Nevertheless, this confirmed the observation that caspases can activate permeability transition and the release of cytochrome c and AIF from isolated mitochondria, in a circular self-amplification loop (Marzo et al., 1998b) . Furthermore, using ANT-containing proteoliposomes and simultaneous measurement of both ANT functions, we showed that the pore function was favored by Bax and inhibited by Bcl-2, whereas, in contrast, the carrier function was favored by Bcl-2 and inhibited by Bax (Belzacq et al., 2003) . Interestingly, mutants of Bax and Bcl-2 that lack the transmembrane a 5 and 6 helices do not interact with ANT in isolated mitochondria as well as in ANT-containing proteoliposomes. In addition, ANT functions proved to be regulated by oxidative stress (for example thiol oxidation of cystein residue 56) (Costantini et al., 2000a) , carbon monoxide (Queiroga et al., 2010) and by interaction with viral proteins such as Vpr and PB1-F2 to modulate cell death (Jacotot et al., 2001; Zamarin et al., 2005) (Figure 2) . Pharmacological studies with CAT and BA suggest that induction of the pore function might be an irreversible process (C Brenner, unpublished data). Interestingly, only the first third of the protein is involved in apoptosis (Bauer et al., 1999) and more precisely, the region 105-156 of ANT2 has been suggested to be the binding domain of ANT with several proteins such as Bax and Bcl-2 (reviewed in Jacotot et al., 2006) . Therefore, it is tempting to postulate that direct interaction of ligands with specific amino acids contained within the ANT sequence provokes a conformational change resulting in a switch from the translocase function to the pore function. The inhibition of the ANT translocase function can also induce apoptosis. This has been elegantly shown with the small molecule, MT-21, a synthetic epolactaene derivatives, which has a g-lactam ring and an alkyl chain at the N-1 position. MT-21 induces apoptosis in human leukemia HL-60 cells (Watabe et al., 2000) and a variety of cell lines (C Brenner, unpublished data) through ANT inhibition and cytochrome c release without any effect on the permeability of the IM (Watabe et al., 2000; Machida et al., 2002) . It was proposed that the mechanisms of MT-21 apoptosis induction could be useful to design a unique strategy to fight cancer cells, but unfortunately, MT-21 cytotoxic effects were abolished by overexpression of Bcl-2 compromising its therapeutic development for anticancer chemotherapy.
Whether the antiport function of ANT is well conserved through evolution (Palmieri and Pierri, 2010) , a role for ANT in the control of cell death has also been reported in other eukaryotes, thereby suggesting an evolutionary conservation of its role in cell death execution (Zhivotovsky et al., 2009) . Thus, only ANT, and neither VDAC nor CypD, is necessary for mitochondrial outer membrane permeabilization and cytochrome c release in yeast (Pereira et al., 2007) and, in Caenorhabditis elegans, the ANT homolog WAN-1 promotes canonical apoptosis by cooperation with the core cell death machinery, namely CED-4/ Apaf-1 and CED-9/Bcl-2 (Shen et al., 2009) .
Four ANT isoforms for cell fate control
Until recently, studies based on purified proteins from rodent organs and cultured cell lines did not address the crucial question of a differential role of ANT isoforms in apoptosis regulation. However, the modification of the relative expression of ANT isoforms (Halestrap and Brenner, 2003) and the fact that MMP process is inhibited in most cancer cells (Kroemer et al., 2007) prompted us to postulate that each isoform could have a different function in apoptosis, and notably that some isoform could be pro-apoptotic and other antiapoptotic.
Expression of ANT isoforms in normal and cancer tissues
The ANT isoforms form a subfamily of mitochondrial carriers composed of four members to date (Palmieri and Pierri, 2010) . Different nuclear genes encode for four homologous proteins, ANT1 to ANT4, which are all located in the mitochondrial IM. The expression of the various isoforms is tissue specific and may depend on the proliferative capacity of the tissue and its energy requirements in term of glycolysis or oxidative phosphorylation (Palmieri and Pierri, 2010) . In humans, the four ANT genes have similar structures and encode similar proteins, with sequence homology among between 80 and 90% between the various isoforms Le Bras et al., 2005) . The initial classification was based on the measurements of ANT1 to ANT3 mRNA levels in rodents and human organs (Lunardi and Attardi, 1991; Faure Vigny et al., 1996; Giraud et al., 1998; Le Bras et al., 2006) . ANT1 mRNA level has been found by reverse transcription polymerase chain reaction (RT-PCR) to be the predominant isoform in heart, brain and muscle, ANT2 mRNA level being the most abundant isoform in proliferative tissues such as lymphoid cells and the liver, and ANT3 being expressed at low levels independently of the tissue type. In breast (MCF7), colon (HT29), cervix (HeLa) and hepato-carcinoma (HepG2) cells, ANT2 mRNA is more abundant than ANT1 (Lunardi and Attardi, 1991; Faure Vigny et al., 1996; Giraud et al., 1998; Le Bras et al., 2006) . Of note, we recently reported that ANT2 mRNA is significantly overexpressed in primary tissues derived from patients with cancer of the breast, uterus, ovary, lung, thyroid gland, bladder and testis as compared with the respective normal tissue (Le . These studies preceded the identification of the fourth isoform, ANT4, by real-time quantitative PCR; ANT4 mRNA was only found in healthy human brain, liver and testis (Dolce et al., 2005) . It remains to be determined how the expression of the four isoforms varies relative to each other in primary cancer tissues.
Recently, the measurement of expression sequence tags (Unigene) established overexpression of ANT2 and ANT3 mRNA and down-regulation of ANT1 mRNA in normal tissues as compared with primary cancer tissues, suggesting the existence of an ANT isoform signature in some cancers. Of note, no reliable information on a sufficient number of cancer patients is available for association with ANT4 expression in the Unigene database.
Mechanisms of regulation of ANT isoform gene expression and impact on cell death
A set of elegant studies unraveled the opposing association of human ANTl and ANT2 mRNA expression with cell proliferation. ANT2 mRNA is highly expressed in proliferating cells and absent or low in non-proliferating cells (either quiescent or terminally differentiated), whereas ANTl mRNA is highly expressed in non-dividing, terminally differentiated skeletal muscle cells, but is absent in proliferating myoblasts (Doerner et al., 1997) . This suggests that the expression of the various ANT genes is different and tightly regulated.
Accordingly, the analysis of the motifs in the 5 0 -flanking regions of ANT genes revealed that their promoter structure and organization are different. The important structural features that delineate the promoter sequences of the four isoforms of ANT and that can influence functional aspect of the ANT protein toward the pro-or the anti-apoptotic program are schematized in Figure 3 .
As the 5 0 -flanking region of the four ANT genes varies with reference to the binding sites of various transcription factors, activation or repression of the genes could be correlated to their methylation status. Thus, each of these human ANT genes contains CpG islands in their proximal promoter regions (Brower et al., 2009b) . Investigations of the methylation status of the three ANT genes, that is ANT1, 2 and 4, in various tissues of mice revealed that this modification controls gene transcription. In comparison with the ANT 4 gene in which the CpG island methylation is essential for gene repression, the CpG islands of ANT1 and ANT2 are hypomethylated, regardless of the gene expression status throughout the tissues of male mice. This study provides an insight into the differential regulation of ANT isoforms in mammals, whereby both the ANT1 and ANT2 genes are capable of active expression, but the ANT4 gene can be repressed throughout somatic tissues. Interestingly, this is one of the first reported observations to clearly show a differential usage of CpG island methylation within a family of genes (Brower et al., 2009b) .
ANT1 isoform is pro-apoptotic and its expression is frequently repressed in cancer
Human ANT1 gene is located on chromosome 4 and is predominantly expressed in heart and skeletal muscles. It possess OXBOX and REBOX sequence elements in the promoter region, in addition to the canonical transcription start sites, the TATA box and CCAAT box elements (Figure 4 ). OXBOX element acts as a positive regulatory element exclusively in muscle cells (Li et al., 1990) . Therefore, the OXBOX and its associated trans-activating factor(s) might account for the high ANTl expression in heart and skeletal muscle in association with F 0 F 1 -ATP synthase b subunit, a component of the oxidative phosphorylation machinery (Li et al., 1989; Neckelmann et al., 1989) . The relatively ANT isoforms family C Brenner et al low level of mitochondrial transcripts in skeletal muscle is inconsistent with the high level of ANTl and F 0 F 1 -ATP synthase b subunit transcripts. These observations suggest that transcriptional control of nuclear-encoded OXPHOS genes may be achieved by both tissue-specific and cell-cycle-specific trans-acting factors (Stepien et al., 1992) . In 1999, a systematic screen for dominant proapoptotic genes led to the identification of ANT1 as a pro-apoptotic factor (Bauer et al., 1999) . Apoptosis induced by ANT1 overexpression was accompanied by enhanced cytochrome c release, and caspases-9 and -3 activation, indicating that its expression facilitates mitochondria-dependent apoptosis (Bauer et al., 1999 , Zamora et al., 2004b . Heterologous overexpression of ANT1 in cardiomyocytes also significantly induces apoptosis with multiple consequences, such as a decrease in NF-kB activity, a down-regulation of Akt activation and Bcl-xL protein levels, a depolarization of the mitochondrial membrane potential and the upregulation of Bax expression (Baines and Molkentin, 2009) . Supporting a pro-apoptotic role of ANT1 in vivo, ANT1 deficiency increases the resistance of mouse brain and neurons to excitotoxic stress (Lee et al., 2009 ). In addition, ANT1 transfection in breast adenocarcinoma cells (MDA-MB-231 cells) in a nude mice model proved to induce apoptosis, to inactivate NF-kB, to increase Bax expression and finally to stimulate tumor regression, validating the hypothesis that ANT1 could be a potent therapeutic target for the treatment of cancer (Jang et al., 2008a) . The pro-apoptotic potential of ANT1 correlates well with its down-regulation in human cancers (see above).
The ANT2 isoform is an MMP inhibitor and can be up-regulated in hormone-dependent cancer Located on the X chromosome, ANT2 is differentially expressed in human tumor cells under hypoxia (Chevrollier et al., 2005b) . The 5 0 region upstream of the start codon contains the TATA box and three putative AP1 control elements near the transcription start site (Figure 4 ). An AP-2-binding site and five SP1-binding sites have also been reported. Two of the SP1 elements (conserved AB box) have been shown to activate ANT2 transcription, while the third element (C box organization) has been shown to inhibit gene transcription. In addition, Luciakova et al. (2008) provided evidence for an upstream-binding site for NF1, an active repressor of the ANT2 gene. ANT2 transcription is up-regulated in growth-activated cells and down-regulated in cells exiting the cell cycle upon serum restriction or density-dependent growth inhibition. The expression of human ANT2 gene in highly proliferative cells is governed by glycolysis-regulated box, a transcriptional element involved in the regulation of glycolytic ATP import into mitochondria (Giraud et al., 1998) . Under aerobic conditions, the specific ROX1 factor binds to an ROX1-binding motif in the ANT2 promoter region and the ANT2 gene is regulated through heme that blocks its expression (Sabova´et al., 1993) . Sequence comparison of the human ANT and the three yeast AAC promoters led to the identification of a 13 bp motif in the ANT2 promoter: CATTGTTATGATT (nt À1196 to À1184 relative to the transcription start) homologous to an AAC3 promoter sequence. This precise sequence regulatory element glycolysis- ANT isoforms family C Brenner et al regulated box confers the binding with specific ROX1-binding factors that critically regulate the expression of the gene in highly proliferating cells (Giraud et al., 1998) .
Increased levels of ANT2 transcripts that occur in response to serum induction are regulated at the level of transcription and transcript stability is unaltered. To date, three distinct suppressor regions in the ANT2 promoter could contribute to regulation under physiological conditions like response to growth activation in a tissue-specific manner (Stepien et al., 1992; Doerner et al., 1997) and in response to differentiation signals in various cell types, including muscles (Lunardi et al., 1992) . The three suppressor regions in the human ANT2 promoter region might have different physiological roles. The proximal Sp1 suppressor (Li et al., 1996) and one upstream suppressor region appear to influence promoter activity in exponentially growing cells, whereas a distal region of the ANT2 promoter (nucleotides -1237 to À546) is required for the down-regulation of the gene (Barath et al., 2004) . Of note, as almost all the SP1-binding sites in the ANT2 promoter are epigenetically masked by methylated CpG islands, it is plausible that the transcriptional activation of the gene is deregulated. Intrigued by the enhanced ANT2 content in some cancer cells (Faure Vigny et al., 1996; Le Bras et al., 2006) , we and others examined the possibility that ANT2 could have cytoprotective effects, that is proliferative and/or anti-apoptotic effects. Thus, it has been speculated that (1) ANT2 could function in a reverse manner to import ATP into the mitochondrial matrix to compensate for the reduced mitochondrial ATP production in cancer cells (Chevrollier et al., 2005a) and (2) could interact preferentially with Bcl-2 to favor a stabilization of mitochondrial membranes through the inhibition of MMP (Belzacq et al., 2003) . Thus, we observed that on the one hand the decrease of ANT2 levels by small-interfering RNA knock-down sensitized cells to apoptosis induction , but on the other hand increased ANT2 levels by stable overexpression in various cell lines (for example HT29 and HeLa cells) promoted chemoresistance (Gallerne et al., 2010) . For instance, ANT2 downregulation renders HeLa cells resistant to Lonidamine, an anti-cancer agent whose effect is based on the induction of the mitochondrial apoptosis pathway through the ANT targeting (Ravagnan et al., 1999; Belzacq et al., 2001a; Gallerne et al., 2010) . Accordingly, suppression of ANT2 by small-interfering RNA in human breast cancer cells induces apoptosis and prevents tumor growth in vitro and in vivo (Jang et al., 2008b) . Thus, the ANT2-mediated cytoprotective effects are strikingly opposite to ANT1 lethal effects. In a limited study on human patients mRNA, we found that ANT2 is frequently overexpressed in hormone-dependent cancers, including ovary, thyroid, testis, breast and cervix correlating with the presumed regulation of an anti-apoptotic protein in cancer. However, a more important study with a larger number of patients is required to validate the expression level of ANT2 as a potential biomarker.
The ANT3 isoform is pro-apoptotic in cellula, but can be up-regulated in cancer Non-rodent mammals including human, cow and dog have an additional ANT3 gene, which is encoded at the pseudoautosomal region of X chromosome and is ubiquitously expressed. The promoter region of the ANT3 isoform contains the classical TATA and CCAAT elements, in addition to as many as 16 SP1-binding sites (Figure 3 ). There are also 13 potential SPlbinding sites within approximately 1250 bp of the transcription start site. The presence of numerous SP1-binding sites could favor apoptosis in a positive manner , because SP1 induces inhibition of cell cycle progression that precedes apoptosis and a transcriptional response targeting genes containing Sp1-binding sites in its promoter region, suggesting Sp1-driven gene transcription . Regarding the role of ANT3 in apoptosis, Zamora et al. (2004a, b) showed that ANT3 exerts a similar effects to ANT1 upon overexpression in HeLa cells, in contrast with the lack of apoptotic activity of ANT2 (Bauer et al., 1999; Zamora et al., 2004a) . Both studies claimed that the effects of ANT1 and ANT3 result from proteinprotein interaction within the PTPC complex because the cytotoxic effects of ANT3 can be prevented by the inhibitors of PTPC (CsA) and ANT (BA), respectively. It was suggested that ANT3 exerts its lethal effects through an interaction with the matrix protein CypD. Both studies reported a lack of cytotoxicity of the ANT2 isoform. Paradoxically, Unigene database reports an upregulation of ANT3 mRNA in numerous human tumors. These findings are counter-intuitive and, therefore, require further investigations to unravel the specific factors associated with ANT3 and its pro-apoptotic activity.
The ANT4 isoform is anti-apoptotic in human cancer cell lines The ANT4 isoform expression is tightly controlled depending on organism and tissue (Dolce et al., 2005) . Interestingly, ANT4 gene is methylated at a long stretch of nucleotides of almost 300 bases just upstream of the predicted transcription initiation site in the promoter region (À212) (Figure 4) . It has been shown earlier that in mouse embryonic stem cells, ANT4 is selectively expressed and uniquely restricted to developing gametes in adult mice, and its promoter hypomethylation was observed only in testis, whereas hypermethylated was detected in somatic cells (Rodic et al., 2005) ; ANT4 gene promoter has a conserved E2F6-binding element, TCCCGC, essential for repression of the ANT4 in somatic tissue (Kehoe et al., 2008) . Consistent with these findings, addition of a CpG-demethylating agent, 5-azadeoxycitidine, to fibroblasts increased gene expression of ANT4, but not the other isoforms (ANT1 and ANT2), thus indicating that unlike ANT4, CpG island DNA methylation perhaps is not a critical factor in the tissuespecific expression of ANT1 and ANT2 (Rodic et al., 2005; Brower et al., 2009a) . Thus, the ANT4 is a pluripotent stem cell-and germ cell-specific isoform of ANT in mouse, and DNA methylation has a primary function in its transcriptional silencing in somatic cells. Moreover, the presence of a COUP-TF-binding sequence element confers transcriptional repression, thereby negatively regulating hormonal induction of target genes (Cooney et al., 1992) . In human cancer cell lines (for example HeLa and HT29), ANT4 overexpression inhibits apoptotic signaling, especially mitochondriamediated cell death (Gallerne et al., 2010) . Thus, ANT4 prevents the loss of mitochondrial transmembrane potential (DCm), the opening of PTPC, the activation of effector caspase-9 and nuclear alterations. The antiapoptotic activity of ANT4 isoform could be mediated by modulation of the ROS steady-state levels. As in this experimental cellular model (Gallerne et al., 2010) , the various ANT isoforms are present, this suggests a possible complex regulatory balance between ANT pro-and anti-apoptotic isoforms and other apoptosis regulatory proteins (that is Bcl-2, GST, catalase) (Gallerne et al., 2010) . Owing to its recent discovery, the specific role of ANT4 in cancer has not yet been investigated. Taken together, promoter analysis of the four ANT isoforms provide insights into the differential regulation of ANTs in mammals and increase our understanding of how these genes developed and their expression was conserved throughout evolution, retaining distinct functions in specific organs and tissues.
Open questions and perspectives
In conclusion, whether all ANT isoforms behave as ADP/ATP carrier across the IM, a central function for the cell metabolism, recent reports support a novel classification based on the differential effect of the various ANT isoforms in cell fate decisions in cancer cells: ANT1 and ANT3 being pro-apoptoptic and ANT2 and ANT4 being anti-apoptotic. This notion of an individual function of each isoform is crucial for the understanding of how ANT isoforms and other mitochondrial proteins (for example Bcl-2, VDAC, CypD, PiC and so on) interact for the regulation of MMP (Kroemer et al., 2007) . It is tempting to postulate that sensitivity of cancer cells to apoptosis could be a function of the ratio of various isoforms, ANT1 and ANT3 being pro-apoptotic and ANT2 and ANT4 being anti-apoptotic, but this requires further validation in large cohorts of clinical samples. The recent advances in our understanding of the differential effects of the various isoforms in cell fate signaling has raised novel questions regarding the molecular determinants of this functional diversity given the strong sequence homologies of the four isoforms. One possibility is that functional differences between the proteins could be a function of an association with different partners and/or different sub-compartmentalization within the mitochondrial IM ( Figure 5 ). In this regard, ANT1 and Figure 5 Hypothetical scheme of topological distribution of ANT isoforms in mitochondrion subcompartments. ANT isoforms fulfill their ADP/ATP exchange function and pore function depending on their association in polyprotein complexes and their submitochondrial localization. The pro-apoptotic isoform, ANT1, has been found in association with VDAC1 and CypP within the PTPC in IM domains in close contact with the OM (Vyssokikh et al., 2001) . Upon death induction, Bax interacts with ANT to favor its lethal pore function, whereas Bcl-2 favors the translocase function and inhibits the pore opening (Marzo et al., 1998a; Belzacq et al., 2003) . In contrast, ANT2, an anti-apoptotic isoform, participate to the ATP synthasome in association with the ATP synthase and the PiC in the cristae (Chen et al., 2004) . In cancer cells, an overexpression of HKII and its association with VDAC has been observed at the surface of mitochondria contributing to the channeling of nucleotides, favoring the metabolic adaptation and inhibiting cell death (Pastorino et al., 2002 ).
ANT2 do not reside in the same area of IM (Vyssokikh et al., 2001) and are not associated with the same polyprotein complexes, that is the PTPC, the ATP synthasome (Beutner et al., 1996; Chen et al., 2004) (Figure 5) . No information regarding the submitochondrial localization of ANT3 and ANT4 are available to date. In addition, differences in the epigenetic modification of ANT isoformes in cancer could help to better understand the differential roles of the isoforms as discussed for other mitochondrial proteins (Smiraglia et al., 2008) . Hence, a complete elucidation of the complex interplay of the various ANT isoforms in cancer cells might have crucial implications for a better understanding of the bioenergetic metabolism of cancer cells and the design of novel mitochondrial-targeted anticancer therapies (Fulda et al., 2010) .
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